Jupiter Life Line Hospital Intrinsic Value
Jupiter Life Line Hospital intrinsic value. Jupiter Life Line Hospital (JLHL) median intrinsic value is ₹378.18 from 9 valuation models (range ₹196–₹521), vs current price ₹253.90 — +48.9% upside (Trading Below Calculated Value), margin of safety 32.9%. Compare with JLHL fair value to assess whether the stock is under or overvalued.
JLHL Valuation Methods Summary — DCF, Graham Number & P/E
Jupiter Life Line Hospital intrinsic value across 9 models vs current price ₹253.90 — upside/downside and value range per method. For current market price and key ratios, visit Jupiter Life Line Hospital share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹420.00 | ₹336.00 - ₹504.00 | +65.4% | EPS: ₹35.00, Sector P/E: 12x |
| Book Value Method | asset | ₹205.45 | ₹184.91 - ₹226.00 | -19.1% | Book Value/Share: ₹205.45, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹196.36 | ₹176.72 - ₹216.00 | -22.7% | Revenue/Share: ₹245.45, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹378.18 | ₹340.36 - ₹416.00 | +48.9% | EBITDA: ₹416.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹520.69 | ₹416.55 - ₹624.83 | +105.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹224.00 | ₹201.60 - ₹246.40 | -11.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹288.40 | ₹259.56 - ₹317.24 | +13.6% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹492.12 | ₹442.91 - ₹541.33 | +93.8% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹402.24 | ₹362.02 - ₹442.46 | +58.4% | EPS: ₹35.00, BVPS: ₹205.45 |
JLHL Intrinsic Value vs Market Price — All Valuation Models
Jupiter Life Line Hospital fair value range ₹196–₹521 vs current market price ₹253.90 across 9 valuation models. Read JLHL dividend history for the complete payout history and dividend yield track record.
JLHL Intrinsic Value Analysis — Undervalued or Overvalued?
Jupiter Life Line Hospital median intrinsic value ₹378.18, current price ₹253.90 — Trading Below Calculated Value by 48.9%, margin of safety 32.9%.
What is the intrinsic value of JLHL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jupiter Life Line Hospital (JLHL) is ₹378.18 (median value). With the current market price of ₹253.90, this represents a +48.9% variance from our estimated fair value.
The valuation range spans from ₹196.36 to ₹520.69, indicating ₹196.36 - ₹520.69.
Is JLHL undervalued or overvalued?
Based on our multi-method analysis, Jupiter Life Line Hospital (JLHL) appears to be trading below calculated value by approximately 48.9%.
JLHL Financial Health — Key Ratios vs Industry Benchmarks
Jupiter Life Line Hospital financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.73 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JLHL Cash Flow Quality — Operating & Free Cash Flow
Jupiter Life Line Hospital operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹253 Cr | ₹149 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹115 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹117 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹137 Cr | ₹95 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹123 Cr | ₹-25 Cr | Positive Operating Cash Flow | 6/10 |